Landscape of industry-sponsored oncology trials across the Thai Society of Clinical Oncology (TSCO): a 12-year multicenter analysis.

@article{wirasorn2026landscape,
  title = {{Landscape of industry-sponsored oncology trials across the Thai Society of Clinical Oncology (TSCO): a 12-year multicenter analysis.}},
  author = {Kosin Wirasorn and Jirapath Wiwitkeyoonwong and Jitlada Juengsamarn and Chanchai Charonpongsuntorn and Pongwut Danchaivijitr and Arunee Dechaphunkul and Nuttinee Inworn and Kunlatida Maneenil and Napa Parinyanitikul and Narichaya Phattana and Parichat Phongthai and Naiyarat Prasongsook and Isaraporn Sangsaikaew and Chatsuda Sookthon and Jirawat Thanestada and Kijjakom Thanasombunsukh and Passakorn Wanchaijiraboon and Charuwan Akewanlop and Nuttapong Ngamphaiboon and TSCO},
  journal = {BMC cancer},
  year = {2026},
  month = jul,
  doi = {10.1186/s12885-026-16583-1},
  url = {https://europepmc.org/article/MED/42958159},
  note = {CC BY-NC-ND},
}

TY  - JOUR
TI  - Landscape of industry-sponsored oncology trials across the Thai Society of Clinical Oncology (TSCO): a 12-year multicenter analysis.
AU  - Kosin Wirasorn
AU  - Jirapath Wiwitkeyoonwong
AU  - Jitlada Juengsamarn
AU  - Chanchai Charonpongsuntorn
AU  - Pongwut Danchaivijitr
AU  - Arunee Dechaphunkul
AU  - Nuttinee Inworn
AU  - Kunlatida Maneenil
AU  - Napa Parinyanitikul
AU  - Narichaya Phattana
AU  - Parichat Phongthai
AU  - Naiyarat Prasongsook
AU  - Isaraporn Sangsaikaew
AU  - Chatsuda Sookthon
AU  - Jirawat Thanestada
AU  - Kijjakom Thanasombunsukh
AU  - Passakorn Wanchaijiraboon
AU  - Charuwan Akewanlop
AU  - Nuttapong Ngamphaiboon
AU  - TSCO
PY  - 2026
DA  - 2026/07/31
JO  - BMC cancer
DO  - 10.1186/s12885-026-16583-1
UR  - https://europepmc.org/article/MED/42958159
AB  - Introduction  Cancer remains a major global health challenge and is a leading cause of morbidity and mortality in Thailand. Industry-sponsored oncology trials (ISOTs) provide critical access to innovative therapies, including targeted agents, immunotherapies (IO), and antibody-drug conjugates (ADCs), particularly in resource-limited settings.Methods  We conducted a retrospective multicenter study to characterize temporal trends, geographic distribution, and clinical trial characteristics of ISOTs across institutions participating in the Thai Society of Clinical Oncology (TSCO) network between January 2012 and September 2024. Data on trial characteristics, geographic distribution, and patient enrollment were collected from institutions affiliated with the TSCO using a standardized data collection instrument.Results  A total of 651 ISOTs were identified. Analyses were performed using available data for each variable, with complete-case analyses (n = 581) applied where complete trial-level information was required. Most trials were conducted in Bangkok (67%), with academic centers accounting for 84%. Provinces with academic centers hosted more trials than those without (62% vs 27%; P < .001). Lung cancer was the most studied tumor type (39%), followed by breast (15%) and gastroesophageal/gastric cancers (10%). Trial numbers increased over time, with phase III studies predominating (64%), although phase I-II trials rose after 2020. Therapeutic focus shifted from chemotherapy to targeted therapies, IO, and ADCs. Sponsorship remained primarily Western, with increasing contributions from Asian companies, particularly China.Conclusion  Within participating TSCO-affiliated institutions, ISOTs were largely concentrated in major urban academic centers, particularly Bangkok. While phase III trials remain predominant, early-phase studies and sponsorship from Asian companies have increased. These findings highlight an evolving oncology research landscape and ongoing disparities in trial distribution.
SN  - 1471-2407
ER  -